Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more
Molecular Partners AG (MLLCF) - Total Assets
Latest total assets as of September 2025: $112.15 Million USD
Based on the latest financial reports, Molecular Partners AG (MLLCF) holds total assets worth $112.15 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Molecular Partners AG - Total Assets Trend (2013–2024)
This chart illustrates how Molecular Partners AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Molecular Partners AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Molecular Partners AG's total assets of $112.15 Million consist of 97.3% current assets and 2.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.3% |
| Accounts Receivable | $2.59 Million | 1.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $49.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Molecular Partners AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Molecular Partners AG's current assets represent 97.3% of total assets in 2024, a decrease from 97.9% in 2013.
- Cash Position: Cash and equivalents constituted 40.3% of total assets in 2024, down from 87.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
Molecular Partners AG Competitors by Total Assets
Key competitors of Molecular Partners AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Molecular Partners AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Molecular Partners AG generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Molecular Partners AG is currently not profitable relative to its asset base.
Molecular Partners AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.28 | 14.33 | 3.08 |
| Quick Ratio | 9.28 | 14.33 | 3.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $97.22 Million | $ 139.10 Million | $ 120.14 Million |
Molecular Partners AG - Advanced Valuation Insights
This section examines the relationship between Molecular Partners AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.69 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | -20.1% |
| Total Assets | $158.53 Million |
| Market Capitalization | $73.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Molecular Partners AG's assets below their book value (0.47 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Molecular Partners AG's assets decreased by 20.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Molecular Partners AG (2013–2024)
The table below shows the annual total assets of Molecular Partners AG from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $158.53 Million | -20.08% |
| 2023-12-31 | $198.35 Million | -24.37% |
| 2022-12-31 | $262.26 Million | +51.89% |
| 2021-12-31 | $172.67 Million | -7.93% |
| 2020-12-31 | $187.55 Million | +78.73% |
| 2019-12-31 | $104.94 Million | -32.37% |
| 2018-12-31 | $155.16 Million | +7.43% |
| 2017-12-31 | $144.42 Million | -21.55% |
| 2016-12-31 | $184.10 Million | -16.09% |
| 2015-12-31 | $219.40 Million | +13.08% |
| 2014-12-31 | $194.02 Million | +76.20% |
| 2013-12-31 | $110.11 Million | -- |